Dyadic International Inc. (DYAI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Dyadic International, Inc. is a global biotechnology platform company developing scalable, non-animal protein production platforms (Dapibus™ and C1) for life sciences, food, nutrition, and bio-industrial markets. Effective August 1, 2025, the company is rebranding as Dyadic Applied BioSolutions to reflect a strategic shift from research-driven to commercially focused operations.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $966,630 | $385,896 | $1,360,202 | $720,513 |
| Net Loss | $(1,793,774) | $(2,045,223) | $(3,821,353) | $(4,054,819) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.07) | $(0.13) | $(0.14) |
| Cash & Equivalents (Total) | $3,974,430 (as of June 30, 2025) | |||
| Investment Securities | $3,252,089 (Short-term: $2.84M; Long-term: $0.41M) | |||
| Convertible Notes (Principal) | $5.09M Outstanding ($4.0M Third Party; $1.09M Related Party) | |||
| Operating Cash Flow (YTD) | $(2,079,746) Used |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 150% in Q2 2025 compared to Q2 2024, driven primarily by new grant revenue ($503,181) from the Gates Foundation and CEPI, and a $250,000 milestone payment from the Inzymes agreement. Research and development revenue decreased due to fewer active collaborations.
- Expense Management: General and Administrative (G&A) expenses decreased by 10.6% in Q2 2025 compared to the prior year, reflecting reductions in business development, legal, and insurance costs. Research and Development (R&D) expenses increased by 22% due to expanded internal initiatives.
- Net Loss Reduction: The net loss narrowed by approximately 12% in Q2 2025 compared to Q2 2024, attributable to higher revenue and lower G&A expenses.
- Liquidity Position: Cash and cash equivalents decreased from $6.5 million at year-end 2024 to $2.1 million at June 30, 2025, though total liquid assets (including investments) remained at approximately $6.9 million.
Guidance, Outlook, and Risks
- Capital Raise: On August 1, 2025, the company closed an underwritten public offering of 6,052,000 shares at $0.95 per share, raising net proceeds of approximately $5.3 million. Management expects existing cash plus these proceeds to fund operations for at least the next 12 months.
- Strategic Shift: The rebranding to Dyadic Applied BioSolutions underscores a focus on commercializing non-therapeutic proteins to accelerate time to revenue.
- Nasdaq Compliance Risks: The company received deficiency notices from Nasdaq regarding failure to maintain the minimum Market Value of Listed Securities ($35 million) and minimum bid price ($1.00). The company has 180 days to regain compliance for both requirements.
- Debt Obligations: The company holds $6.0 million in aggregate principal of 8% Senior Secured Convertible Notes due March 2027. A second amendment in May 2025 moved the redemption date to December 1, 2026.
- Going Concern: While the recent capital raise alleviates immediate liquidity concerns, the company continues to incur losses and relies on future financing or commercialization success to sustain long-term operations.
Investor Verification Checklist
- Nasdaq Compliance Status: Verify the company's progress in meeting the $35 million Market Value and $1.00 bid price requirements by the December 2025 and January 2026 deadlines.
- Grant Utilization: Confirm the spend rate and revenue recognition timeline for the Gates Foundation ($3.1M total) and CEPI ($2.4M eligible) grants, as these are significant revenue drivers.
- Commercial Milestones: Monitor the achievement of the $500,000 productivity milestone with Proliant (expected Q3 2025) and the commercial launch of the Inzymes dairy enzyme product (expected late 2025).
- Debt Conversion: Track the conversion price of $1.40 per share for the convertible notes and potential dilution if holders exercise conversion rights.
- Use of Proceeds: Review how the $5.3 million from the August 2025 offering is allocated between working capital, product development, and sales/marketing.